PPA
IMDX

Parametric Portfolio Associates’s Insight Molecular Diagnostics IMDX Stock Holding History

Parametric Portfolio Associates’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$22K Sell
748
-279
-27% -$8.92K ﹤0.01% 3659
2021
Q4 		$45K Sell
1,027
-235
-19% -$13.5K ﹤0.01% 3602
2021
Q3 		$90K Sell
1,262
-376
-23% -$34.6K ﹤0.01% 3544
2021
Q2 		$188K Buy
1,638
+782
+91% +$76.4K ﹤0.01% 3416
2021
Q1 		$89K Buy
+856
New +$81.3K ﹤0.01% 3978
2020
Q3 		– Sell
-771
Closed -$29K – 3960
2020
Q2 		$29K Buy
771
+156
+25% +$8.06K ﹤0.01% 3884
2020
Q1 		$30K Sell
615
-30
-5% -$1.47K ﹤0.01% 3875
2019
Q4 		$29K Sell
645
-1,161
-64% -$41.9K ﹤0.01% 3942
2019
Q3 		$76K Buy
+1,806
New +$71K ﹤0.01% 3872
2018
Q3 		– Sell
-630
Closed -$32K – 3962
2018
Q2 		$32K Buy
+630
New +$31K ﹤0.01% 3864

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Parametric Portfolio Associates's IMDX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Insight Molecular Diagnostics (IMDX) stake by 27% in Q1 2022, selling an estimated $8.92K and leaving 748 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3659.

Parametric Portfolio Associates first reported a position in IMDX in Q2 2018 and has held it in 10 quarters since. The position peaked at $188K in Q2 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Parametric Portfolio Associates held 748 shares of Insight Molecular Diagnostics worth $22K as of Q1 2022.
  • Parametric Portfolio Associates sold 279 Insight Molecular Diagnostics shares in Q1 2022, an estimated $8.92K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3659 holding.
  • Parametric Portfolio Associates first reported a position in Insight Molecular Diagnostics in Q2 2018 and has held it in 10 quarters since.
  • Parametric Portfolio Associates's Insight Molecular Diagnostics position peaked at $188K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.